Patents by Inventor Tahamtan Ahmadi

Tahamtan Ahmadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY AND TAXANE COMBINATION THERAPY
    Publication number: 20240109972
    Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
    Type: Application
    Filed: December 7, 2021
    Publication date: April 4, 2024
    Inventors: Ugur SAHIN, Alexander MUIK, Ulf FORSSMANN, Maria JURE-KUNKEL, Manish GUPTA, Tahamtan AHMADI, Kathy AMIRI, Gaurav BAJAJ
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240034812
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: September 10, 2021
    Publication date: February 1, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
    Patent number: 11858995
    Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 2, 2024
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Jenny Jianlin Chen, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11845805
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 19, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230355753
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230357440
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ
  • Methods of Treating High Risk Multiple Myeloma
    Publication number: 20230340145
    Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
    Type: Application
    Filed: February 27, 2023
    Publication date: October 26, 2023
    Inventors: Tahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20230312757
    Abstract: Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Jenny J. CHEN, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BRElJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230312758
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, cHRISTOPHER W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230312759
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of car regimen of gemcitabine and oxaliplatin (GemOx).
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Patricia GARRIDO CASTRO
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20230227570
    Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Tahamtan AHMADI, Manish GUPTA, Tommy R. LI, Roberto OLIVERI, Dena DEMARCO, Ida HIEMSTRA, Christopher CHIU, Brian ELLIOTT, Ada AZARYAN
  • Methods of treating high risk multiple myeloma
    Patent number: 11618787
    Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 4, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Tahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11608383
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: March 21, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11548952
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 10, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11535679
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 27, 2022
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij
  • DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER
    Publication number: 20220315661
    Abstract: The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages.
    Type: Application
    Filed: May 11, 2020
    Publication date: October 6, 2022
    Inventors: Ulf FORSSMANN, Manish GUPTA, Jens Thing MORTENSEN, Merete ELLEKILDE-PEDERSEN, Marije Berber OVERDIJK, Tahamtan AHMADI
  • AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER
    Publication number: 20220273809
    Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Inventors: Maarten JANMAAT, Nora PENCHEVA, Esther Cornelia Wilhelmina BREIJ, Julia BOSHUIZEN, Daniel Simon PEEPER, Ulf FORSSMANN, Tahamtan AHMADI, Patricia Garrido CASTRO
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20220144964
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Application
    Filed: December 22, 2021
    Publication date: May 12, 2022
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W. L. CHIU, Esther C. W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20220119544
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: December 21, 2021
    Publication date: April 21, 2022
    Inventors: Brian Elliott, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20220112309
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of gemcitabine and oxaliplatin (GemOx).
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Patricia Garrido CASTRO